RVPH — Reviva Pharmaceuticals Holdings Inc.
NASDAQ · Healthcare · Biotechnology
$0.51
+$0.03 (+6.25%)
Reviva Pharmaceuticals Holdings Inc. (RVPH) is a biotechnology company listed on NASDAQ. It is led by Laxminarayan Bhat Ph.D., based in 10080 N. Wolfe Road, Cupertino, CA, United States, 95014, with about 14 employees. Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Net income was -$4.0M. RVPH currently screens at market cap $7.6M.
Use this RVPH page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RVPH quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RVPH SEC filings page. Lician reads the product cache first so this HTML stays unique to Reviva Pharmaceuticals Holdings Inc. even when a live quote feed is slow.
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
RVPH Key Statistics
Market Cap
$7.64M
Volume
42,306
Previous Close
$0.46
Day Range
$0.45 – $0.52
P/B Ratio
0.44
EPS
$0.00
Revenue
$0.00
Net Income
-$29.92M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
14
RVPH Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$29.92M | -$39.26M | -$28.26M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 |
Total Assets
$15.50M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$13.50M
Operating Cash Flow
-$33.54M
Free Cash Flow
$0.00
Reviva Pharmaceuticals Holdings Inc. Company Information
- Founder, CEO, President & Director
- Laxminarayan Bhat Ph.D.
- Headquarters
- 10080 N. Wolfe Road, Cupertino, CA, United States, 95014
- Website
- www.revivapharma.com
- Phone
- 408 501 8881
- IPO / Founded
- 2018-10-18
- Sector
- Healthcare
- Industry
- Biotechnology